RBC Capital lowered the firm’s price target on Thermo Fisher (TMO) to $718 from $767 but keeps an Outperform rating on the shares. The company’s Q3 earnings call was “more positive” that its results, and the firm remains positive on the stock, with Life Sciences Solutions segment seeing bioproduction momentum and sales with Laboratory Products and Biopharma Services segment not seeing biotech slowdown, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMO:
- Thermo Fisher price target lowered to $620 from $625 at Bernstein
- Thermo Fisher price target lowered to $622 from $632 at Baird
- Thermo Fisher price target lowered to $660 from $670 at Wells Fargo
- Thermo Fisher price target lowered to $610 from $620 at Barclays
- Thermo Fisher Scientific Reports Earnings: Did it Beat Estimate Forecasts?